Welcome to PRI

To see what kind of research was presented at last January’s Annual Research Forum in oral and poster presentations, click here.

More details about the upcoming Annual Research Forum on Jan. 23, 2016 coming soon!









Founded in 2002, the Pharmaceutical Research Institute (PRI) at Albany College of Pharmacy and Health Sciences is a center for drug discovery and development.

PRI investigators possess expertise in fields that include nanotechnology, medicinal chemistry, molecular biology, and cell biology.

Areas of focus include: hematology/oncology, cardiovascular (dyslipidemia), ophthalmology, vascular diseases, neurology, and inflammation.

As part of its mission, PRI is also engaged in teaching and learning. Pharmacy students, graduate students, and visiting scholars from around the world visit the Institute to conduct research and learn the latest advances across a wide range of therapeutic areas.

Recent Publications

  • Extrinsic Targeting Strategies Against Acute Myeloid Leukemic Stem Cells

    Despite advances in the treatment of acute myeloid leukemia (AML), patients still show high relapse and resistance against conventional chemotherapy. This resistance is related to a small clone referred to as Leukemia Stem Cells (LSCs). New targeted strategies are directed against the LSCs’ extrinsic regulators including their microenvironment such as a CXCR4 antagonist that is used to interfere with LSCs’ homing. Targeting LSCs’ surface molecules such as CD33 for selective elimination of LSCs has variable degrees of success that may require further assessments. Trials with CARs cells were effective in eradication of acute lymphoblastic leukemia, and they may have an effective role also in AML. Other strategies are directed against the intrinsic regulators such as self-renewal mechanisms and epigenetic reprogramming of LSCs. This review highlights targeting of the extrinsic regulators of the LSCs and identifies biological differences between them and normal hematopoietic stem cells.

    Read more
  • Intrinsic Targeting Strategies Against Acute Myeloid Leukemic Stem Cells

    Acute myeloid leukemia (AML) is ranked as the sixth highest cause of cancer-related deaths. Leukemic stem cells (LSCs) are suspected to be the cause of AML’s relapse and resistance to conventional chemotherapy. LSCs and normal hematopoietic stem cells (HSCs) share many properties such as self-renewal capacity, which appears to be responsible for the maintenance of leukemia cells in bone marrow and peripheral blood. In recent years, significant achievement in understanding the LSCs’ biology and regulators has been made that opens new windows for targeting LSCs. Some of these strategies are directed against the signaling pathways such as Wnt, and others are directed against transcription factors such as nuclear factor kappa B (NF-κB). Research is also ongoing to look for epigenetic reprogramming of LSCs by targeting DNMT3A mutation. This review highlights studies that target the intrinsic LSC regulators.

    Read more